Disclaimer: This information is sourced from reputable financial sites such as Reuters, Bloomberg, and TradingView. It reflects thorough research, and economic events can considerably alter market conditions, potentially changing the forecast; however, you are encouraged to conduct your own research and seek professional advice to make informed decisions.
Oncopeptides AB (ONCO.SE) is a Swedish biotech company making waves in the pharmaceutical industry with its innovative approach to developing targeted therapies for difficult-to-treat hematological diseases. As investors and market analysts look ahead to the coming years, there is growing interest in the potential trajectory of Oncopeptides' share price.
This article delves into expert predictions and market analyses for Oncopeptides' stock performance from 2025 to 2030, offering insights into the company's financial health, product pipeline, and growth prospects.
Key takeaways: Oncopeptides share prediction
Oncopeptides AB (ONCO.SE) is poised for potential growth in the coming years, with analysts projecting positive share price trajectories from 2025 to 2030. The company's robust pipeline, successful commercialization of its lead product, Pepaxto, and strong financial position contribute to the optimistic outlook. While short-term predictions suggest significant upside potential, long-term predictions vary widely, emphasizing the importance of considering multiple factors such as market expansion, clinical trial results, and overall economic conditions when evaluating the company's future performance.
*Source: TradingView.com
Oncopeptides share prediction 2025
The Oncopeptides AB (ONCO.SE) share projection 2025 varies significantly across different sources. According to reports, the stock price is predicted to drop dramatically from 2.220 SEK to 0.000188 SEK, representing a change of -99.992%. This prediction suggests a significant stock value decline over the next year.
In contrast, other sources provide more optimistic predictions such as an average 1-year price target of 6.022 SEK, with a low of 3.599 SEK and a high of 8.979 SEK, based on Wall Street analysts' estimates.
TradingView also offers a prediction with a price target of 9.13 SEK, a maximum estimate of 14.00 SEK, and a minimum estimate of 4.50 SEK. This suggests a significant upside potential for the stock. However, it is essential to note that these predictions are based on analyst estimates and may not reflect the stock’s actual performance.
Experience Skilling's award-winning platform
Try out any of Skilling’s trading platforms on the device of your choice across web, android or iOS.
Oncopeptides share prediction 2030
Current analyst price targets for ONCO.SE focus on the shorter term, with a 12-month consensus price target of around 9.13 SEK, according to TradingView. This represents a potential upside of approximately 114% from the current share price of 2.29 SEK as of August 2024. However, these near-term projections do not necessarily reflect the company's long-term growth prospects and potential share price appreciation by 2030.
Oncopeptides AB is a biotech company focused on developing treatments for difficult-to-treat cancers. The company's lead product, Pepaxti (melflufen), has faced challenges in the US market, with the FDA confirming the withdrawal of the drug in the US in Q1 2024. Despite this setback, Oncopeptides has made progress in Europe, particularly in Spain and Germany, and has established a new partnership in the Middle East and North Africa (MENA) region. These developments provide a foundation for future growth as the company expands its market reach to impact more patients globally.
Factors that could influence Oncopeptides' share price performance leading up to 2030 include the successful commercialization of Pepaxti in Europe and other markets, the development of additional pipeline products, and the company's profitability. In the Q1 2024 report, Oncopeptides' management expressed confidence in the company's growth potential despite facing challenges from seasonal flu and winter infections. The company also announced a fully guaranteed rights issue of SEK 314 million to reach profitability by 2026, which could be a positive catalyst for the stock if achieved.
FAQs
1. Oncopeptides shares dividend
As a biotech company focused on developing treatments for difficult-to-treat cancers, Oncopeptides appears to prioritise investments in research, development, and commercialization of its lead product, Pepaxti (melphalan flufenamide) rather than distributing profits to shareholders.
The company's financial reports indicate that Oncopeptides is still in the early stages of commercialization and is yet to be profitable. In Q2 2024, the company reported a net loss of SEK 73.2 million despite a 60% increase in revenue compared to the previous quarter. The focus remains on expanding Pepaxti’s market access in Europe and investing in the development of its research pipeline, including the SPiKE platform.
Given the nature of the biotech industry and Oncopeptides' current stage of development, it is common for the company to reinvest any available funds into growth initiatives rather than distributing dividends. Many biotech companies only pay dividends once they have achieved consistent profitability and have sufficient cash flow to support their growth plans and shareholder returns.
What's your Trading Style?
No matter the playing field, knowing your style is the first step to success.
2. Is Oncopeptides Stock a buy or sell?
Based on the information gathered from multiple reputable sources, it is difficult to say definitively whether Oncopeptides stock is a buy or sell. The company, which focuses on developing targeted therapies for difficult-to-treat hematological diseases, has garnered interest from institutional investors, suggesting some credibility among professional investors. However, relying solely on institutional ownership is not advisable, as even large investors can sometimes make poor investment decisions.
Analysts' price targets for Oncopeptides stock provide insight into the company's potential. The average one-year price target is 6.02 kr, with predictions ranging from a low of 3.60 kr to a high of 8.98 kr. These price targets are set by analysts who consider the stock's projected and historical earnings and other factors to determine a fair value. However, it is essential to note that analyst ratings and price targets are not guarantees of future performance and should be considered alongside other research.
Examining the company’s financial health and growth prospects is crucial when evaluating a stock. Oncopeptides' predicted annual revenue for 2027-12-31 is 515MM, which could indicate growth potential. However, without more context about the company's historical revenue and profitability, assessing whether this projection is realistic or achievable is challenging.
Ultimately, buying or selling Oncopeptides stock should be based on an individual's investment goals, risk tolerance, and thorough research.
3. Who is the major shareholder of Oncopeptides?
According to the analysis of Oncopeptides AB's shareholder structure, the company has a diverse group of major shareholders, including institutions, private equity firms, and individual investors. The largest shareholder is HealthCap, a private equity firm that owns 20% of the outstanding shares. HealthCap is followed by Industrifonden, another institutional investor with a 13% stake in the company.
Other significant shareholders include Max Mitteregger Kapitalförvaltning, a private investment firm with a 5.7% ownership. Hedge funds collectively own 5.7% of Oncopeptides' shares, indicating that these investment vehicles see potential value in the company. Insiders, such as board members and executives, also have skin in the game, holding shares worth approximately 99 million Swedish kronor.
The general public holds a 23% stake in Oncopeptides, demonstrating that retail investors have confidence in the company's prospects. As a group, private equity firms own a substantial 45% of the company, which suggests that these sophisticated investors believe in Oncopeptides' long-term growth potential.
